Navigation Links
Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Date:11/7/2007

ents' utility scores were estimated and used to calculate QALYs. To determine costs, in addition to the costs of HA, patients who responded to HA treatment were assigned costs of health care utilization attributed to patients without OA, and non-responders were assigned costs of health care resources consumed by OA patients. Cost- effectiveness was expressed as average and incremental cost per QALY.

The responder rate for patients in the HA treatment arm was approximately 83 percent, and the mean QALY gained was 0.0877 for each patient responding to treatment with HA over baseline values. When the change of QALY of the non- responders was set as zero, the HA treatment yielded a cost-utility ratio of $38,964, while that of the control group ranged from $36,077 (assuming a 75 percent response rate) to $139,648 (25 percent response rate).

The study concluded that the cost-utility ratio for EUFLEXXA(TM) is within the range needed to adopt a new technology, and that the product's wider adoption would result in greater savings to the health care system.

About EUFLEXXA(TM)

EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (eg, acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were "pain free" and "symptom free" with EUFLEXXA(TM).(2)

The process used to manufacture EUFLEXXA(TM) produces the HA that most closely resembles the HA in healthy human synovial fluid and the most highly purified HA product available today. In addition, since it is not derived from an avian source (chicken or rooster combs), the risk of reactions related to avian proteins is eliminated.(3-8
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ONCOLOGY ... engaged in the development and commercialization of novel, ... it has met with the U.S. Food and ... filing of an Investigational New Drug (IND) application ... a result of the meeting, Neovia has clarified ...
(Date:6/1/2015)... Novel t reatments   entering the squamous ... GBI Research . The ... primarily by the introduction of numerous premium therapies, particularly in ... combine with generic chemotherapies. Analysis from business intelligence ... to 2020 - forecasts the value of the NSCLC ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... Pharmasset, Inc.,(Nasdaq: VRUS ), a clinical stage pharmaceutical ... viral,infections, reported financial results for the fiscal year ended September ... cash and cash,equivalents and short term investments. , ... Clevudine , ...
... PHILADELPHIA, December 11, Rosetta Genomics, Ltd. (NASDQ: ROSG), ... the,commercial availability of its first diagnostic test, miRview(TM) ... Genomics,CLIA-certified lab in Philadelphia. , ... may contact 1-888-522-7971, or visit the,company,s website ...
Cached Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... Atlanta, GA (PRWEB) June 01, 2015 ... leading publisher of clinical journals in the areas of ... pleased to announce that it has expanded upon its ... newest journal, Hospital Medicine Practice, in a mobile ... smartphones and tablets. , “We are very excited ...
(Date:6/1/2015)... The session, entitled “Building the Blueprint for Tomorrow’s Vehicle ... Automotive Americas, senior representatives from Ford and Delphi, ... by Andy Gryc of CX3 Marketing. The discussion will ... software in connected vehicles and autonomous cars, and will ... ecosystem can fit into new vehicle software. , ...
(Date:6/1/2015)... Strategic Radiology (SR) announced today that Rome Radiology Group ... SR coalition of progressive, independent radiology groups geographically dispersed ... have access to collective resources in all aspects of ... of subspecialized radiology services. With the addition of RRG, ... based radiology group practices. , “We are all ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 It ... and sanitary in order to protect both care providers ... that there needs to be a way to put ... Line is a line of home-healthcare products that promotes ... care providers and patients safe from germs and disease. ...
Breaking Medicine News(10 mins):Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 2Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 4
... came into being in the seventies, evolved into an essential component ... increase with mounting pressure on pharma and biotech companies to lower ... projected to exceed $26.2 billion by the year 2012. , ... ...
... that allows more efficient use of larger cleanrooms. , ... ... designer, fabricator and installer of cleanrooms and cleanroom equipment ... into the AireCell line of extrusions. The new extrusion allows ...
... SuperFood with Super Antioxidant provides ... environmental stress, ORLANDO, Fla., Oct. 21 ... (Chennai, India) are jointly introducing a,new organic ... complex,of organic spirulina and astaxanthin in a ...
... 21, 2008) Gastroesophageal reflux disease (GERD) is ... in GI and primary care clinics, however physicians ... trials of medications and their own observations and ... Gastroenterological Association (AGA) Institute has published evidence-based guidelines ...
... of $25 Tickets Available for Purchase at the Pine Avenue ... Entrance to the Long Beach Convention Center, LOS ANGELES, ... The Village event tonight from 5:00 p.m. to 9:00 p.m.,at the ... Night at The Village will,transform the Long Beach Convention Center,s exhibit ...
... Promotes Positive Options, Educates about Dangers of Alcohol, ... 24 school districts have been named by the ... 2008 Alcohol Awareness Poster,Contest., The awards recognize ... message that underage drinking is dangerous. The,PLCB,s annual ...
Cached Medicine News:Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 4Health News:Gerbig Engineering Introduces 7 " Deep Extrusions for Cleanroom Construction 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:AGA releases evidence-based GERD guidelines 2Health News:AGA releases evidence-based GERD guidelines 3Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 2Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 2Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 4
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.8 mm angled double bevel. Blade tip dimension: N/A x 2.8 mm x N/A....
Medicine Products: